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PPARγ/mTOR signalling: striking the
right balance in cartilage homeostasis
Francesco Dell’Accio,1 Joanna Sherwood2
Osteoarthritis (OA) is still a highly preva-
lent and disabling disease for which we do
not have a cure. In the last decade,
however, the unravelling of molecular
mechanisms controlling joint homeostasis,
the advances in targeting technologies, and
the improvement of animal models allow-
ing the use of mouse genetics has led to the
identiﬁcation of molecular targets that, in
animal models,1–4 and possibly also in
humans5 can arrest disease or even revert
its course. Such strategies include blockade
of extracellular matrix-degrading enzymes,6
hypoxia-inducible factor 2α blockade3 4 to
prevent chondrocyte hypertrophy, the
support of parathyroid hormone/parathy-
roid hormone related protein signalling—
an injury-induced homeostatic mechanism
affecting both cartilage homeostasis and
bone remodelling,2 improving bone turn-
over using strontium ranelate,5 and block-
ade of the ﬁlamin-core binding factor
interaction thereby supporting chondrocy-
tic differentiation using kartogenin.7
Although only strontium ranelate has been
tested in the clinic, there is little doubt that
the availability of multiple targets will
stimulate and instruct the experimentation
needed to bridge the gap to the clinic.
In this issue of the journal, Vasheghani
et al8 have demonstrated that
PPARγ-driven mTOR (mammalian target
of rapamycin) inhibition protects cartilage
from experimental OA, at least in part by
supporting autophagy,8 a process that, by
suppressing protein synthesis and enabling
the use of cellular components to generate
energy, allows cells to escape death in con-
ditions of stress or lack of nutrients.9
The authors previously reported that
cartilage-speciﬁc disruption of the gene
encoding for the transcription factor
PPARγ results in spontaneous OA in
mice.10 To ensure that this phenotype was
not driven by skeletal dysplasia determined
by the absence of PPARγ during develop-
ment, they generated a new mutant in
which PPARγ could be deleted postnatally
in chondrocytes upon administration of
doxycycline. The mice did not develop
spontaneous OA, but became more suscep-
tible to experimental OA induced by desta-
bilisation of the medial meniscus (DMM).
The more severe OA phenotype in PPARγ
knockout (KO) mice was associated with
increased expression of Mmp13, Adamts5,
and with a higher number of apoptotic
chondrocytes.
The same group11 and others12 had pre-
viously shown that disruption of mTOR, an
intracellular kinase promoting cell metabol-
ism, growth, energy usage and differenti-
ation, protected mice from experimental
OA with reduced chondrocyte apoptosis,
increased autophagy and lower expression
of catabolic markers.11 12
Therefore they then tested the hypoth-
esis that the worse OA outcome in PPARγ
KO mice was due to enhanced mTOR
signalling.
mTOR is the catalytic subunit of two
distinct molecular complexes, mTORC1
and mTORC2, which are differently regu-
lated, have different downstream effectors
(Raptor and Rictor13 14) and lead to dis-
tinct downstream effects.9
Loss of PPARγ resulted in increased
expression of mTOR, with a correspond-
ing decrease in autophagy markers in
resting conditions or following DMM.
Most strikingly, double KO of mTOR
and PPARγ were protected from DMM-
induced OA with a phenotype similar to
that of the previously published mTOR
KO,11 thus establishing that, in this context,
PPARγ is epistatic to mTOR. This is not
trivial, because, in different contexts, and in
particular in the regulation of lipid synthe-
sis, mTOR positively regulates the activity
of PPARγ.15 It is therefore possible that
either the epistatic relationship of these two
molecules is context dependent, or that
PPARγ is activated by mTOR and operates
a negative feedback loop to limit mTOR
activation.
These data suggest that mTOR is a patho-
genic factor in cartilage, which facilitates
cell death. A few months earlier, however,
Chen and Long16 reported that disruption
of the mTOR complex 1 (mTORC1) in
chondrocytes, through either knockout of
mTOR or of the mTORC1-speciﬁc medi-
ator Raptor, resulted in a chondrodysplasia
characterised by short skeletal elements,
with delayed endochondral bone formation.
In this context, chondrocyte proliferation
was not affected, apoptosis was delayed, not
increased, and the phenotype was largely
contributed by decreased protein synthesis,
decreased extracellular matrix formation,
and reduced cell volume, all in keeping with
the known functions of mTOR and
mTORC1 in particular.
How do we reconcile the ‘anabolic’
function of mTOR identiﬁed by Chen
and Long16 in cartilage development
with the pathogenic one identiﬁed by
Vasheghani et al8 in OA? One could
speculate that whereas in embryonic
development mTOR is required to
support the high energy consumption
necessary for skeletal growth and permit-
ted by the abundance of nutrients and
absence of injury, in certain phases of
OA, particularly in the early phases fol-
lowing injury, rather than trying to com-
pensate to the matrix loss with more
anabolic activity, chondrocytes have to
‘lay low’ to escape cell death until the
noxious factors are scavenged (ﬁgure 1).
This hypothesis would also reconcile this
literature with other reports showing an
anabolic effect of AKT, also involved in
mTOR signalling in cartilage.17 18
mTOR expression and activity is regulated
by a number of signalling pathways, avail-
ability of nutrients and metabolism, and
therefore PPARγ/mTOR signalling is ideally
placed to allow chondrocytes to match what
would be desirable following injury (repair,
anabolism) with the constrains of a patho-
logic environment (absence of nutrients,19
inﬂammation, comorbidities, etc).
mTOR is not only an inhibitor of
autophagy, but also positively regulates
protein synthesis, cell proliferation, differ-
entiation, cell size, and extracellular
matrix production,9 all processes that in
one way or another play a role in OA
pathology. Equally, several factors other
than PPARγ and inﬂammation regulate
mTOR activity, including availability of
nutrients, metabolism and mechanical
stress, which are also associated with OA
susceptibility and progression.
Apparently in contrast with the well-
established role of mTOR in supporting
anabolism, protein synthesis and extracel-
lular matrix production including in car-
tilage,9 16 Vasheghani et al found that
PPARγ KO chondrocytes had increased
mTOR but decreased expression of the
anabolic markers Aggrecan and COL2A1
mRNA, and PPARγ overexpression
resulted in upregulation of COL2A1 and
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Aggrecan mRNA. Therefore the upregula-
tion of Aggrecan and COL2A1 mRNA
may be functions of PPARγ which are
independent of mTOR. Alternatively,
although not addressed in the article,
mTOR suppression of matrix production
takes place at the level of protein synthe-
sis,9 16 and therefore the upregulation of
COL2A1 and Aggrecan mRNA may not
translate into protein. Finally, the upregu-
lation of these markers downstream of
PPARγ signalling may be the result of an
improved survival of differentiated chon-
drocytes rather than a genuine transcrip-
tional outcome.
The article by Vasheghani et al8 is also
important because both mTOR and
PPARγ are pharmacologically targetable
with several compounds already available,
including PPARγ agonists20 21 and several
inhibitors of mTOR, the most well-known
of which is rapamycin.
So, besides the availability of molecules
with a suitable safety proﬁle, tolerability
and appropriate pharmacokinetics, what
are the gaps in knowledge that we need to
ﬁll before clinical translation can be
attempted?
The ﬁrst hurdle is that mTOR and
PPARγ are involved in many different pro-
cesses and their activity is highly context
dependent. Within the same cell, mTOR
can lead to different biological outcomes
depending on its association within
mTORC1 and mTORC2 and the subcel-
lular compartmentalisation,22 and its
activity is inﬂuenced by many other sig-
nalling pathways including those activated
by WNTs, IGF-1 and inﬂammatory cyto-
kines.9 The understanding of how these
different signals utilise common compo-
nents of the intracellular machinery and
yet achieve speciﬁc outcomes is only
starting to bud, but its accomplishment
will allow the rational design of speciﬁc,
safer and more efﬁcacious drugs.
A second issue highlighted by this
work is that for effective targeting of
adaptive mechanisms we need to be able
to identify patients whose disease is
driven by such mechanisms at the time of
intervention. For example, in the article
by Vasheghani et al8, mTOR was upregu-
lated in PPARγ KO mice also in resting
conditions, but the difference in cartilage
cellularity was evident only after injury.
This is clearly an advantage in terms of
safety, because it will not affect healthy
cartilage, but also carries its challenges: it
might be possible that in different subsets
of patients, or in different phases of the
disease, for instance when repair is
important, shutting down energy con-
sumption and protein synthesis may be
undesirable.
A ﬁnal consideration is that, as mTOR
and PPARγ are involved in many meta-
bolic processes, it is highly likely that
comorbidities including diabetes and
obesity, nutrition and ageing will have
profound consequences on the effect of
targeting these pathways effectively and
safely. A new class of biological readouts
and biomarkers are therefore needed that
are relevant not necessarily to the disease
outcome (eg, cartilage breakdown), but
that report on the activity of speciﬁc
disease mechanisms to predict response to
therapy.
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